Bracco Imaging Spa
🇮🇹Italy
Clinical Trials
40
Active:38
Completed:1
Trial Phases
2 Phases
Phase 1:8
Phase 3:1
Drug Approvals
63
NMPA:51
CIMA_AEMPS:11
EMA:1
Drug Approvals
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Phase 1
8 (88.9%)Phase 3
1 (11.1%)No trials found
News
Blue Earth Therapeutics Secures $76.5M to Advance PSMA-Targeted Radioligand Therapies
• Blue Earth Therapeutics has secured $76.5M in Series A financing to advance its radiohybrid PSMA-targeted radioligand therapies. • The funding will support Phase II studies of Lutetium (177-Lu) rhPSMA-10.1 and Actinium (225-Ac) rhPSMA-10.1 for prostate cancer. • Blue Earth aims to compare its rhPSMA candidates with first-generation prostate cancer radioligand therapies to improve patient outcomes. • The investment reflects growing interest in the theranostics market, projected to reach $39 billion by 2032, driven by radiopharmaceuticals.